Drug Profile
Crenigacestat - Eli Lilly and Company
Alternative Names: JSMD-194; LY-3039478Latest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Fred Hutchinson Cancer Research Center; National Cancer Institute (USA)
- Class Amides; Antineoplastics; Benzazepines; Fluorinated hydrocarbons; Pyridines; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Precursor T-cell lymphoblastic leukaemia-lymphoma
- No development reported Cancer; Liver cancer; Lymphoma; Multiple myeloma; Solid tumours
Most Recent Events
- 08 Jan 2024 Fred Hutchinson Cancer Research Center in collaboration with Juno Therapeutics terminates a phase-I trial in Multiple myeloma in USA (PO) due to SRC low accrual policy (NCT03502577)
- 30 May 2023 Eli Lilly and Company completes a phase-I trial in Solid tumours in Japan (NCT02836600)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Metastatic disease) in Denmark (PO)